Medical isotope developer IsoRay Medical has completed a license agreement with Dr. Reddy's Laboratories for exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation used in brain cancer treatment.
Iotrex is a critical component in the GliaSite radiation therapy system, a balloon catheter device used in the treatment of many forms of brain cancer. The GliaSite system places a specified high dose of a liquid radiation source in the areas most likely to contain cancer after brain tumor removal and is less likely to damage healthy brain tissue. GliaSite attacks the remaining diseased area, conforming to the resected tumor bed.
The Iotrex licensing agreement is a major step toward the company's U.S. Food and Drug Administration (FDA) submission for final approval prior to an anticipated sales launch in the U.S. in August, IsoRay said.
